Fact CheckerSign in

NCT07187596Active, not recruiting

Mortality Outcome of Controlled Hypertension

Progressive Elaboration Framework of Mortality Outcomes in Controlled Hypertension: A Qualitative Evidence Synthesis Systematic Review and Individual Participant Data Meta-Analysis 1

Source: ClinicalTrials.gov · Last updated 29 Jul 2026

Brief summary (registry, in English)

This review focuses on the assumption of mortality outcome of participants remaining label hypertension care is adequately managed when pressure targets are met with both qualitative and quantitaive method.

Status (registry)
Active, not recruiting
Study type
Observational
Enrollment
2547 (estimated)
First submitted
9 Sept 2025
Start date
18 Sept 2025
Primary completion date
18 Dec 2026
Lead sponsor
DejthidaNathaphong
NCT number
NCT07187596

What you commit to

  • Study type: Observational
  • Planned participants: 2547
  • From 18 Sept 2025 to the primary completion date, 18 Dec 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Criteria the registry did not label

  • Inclusion:
    • Human birth in all sex chromosomes.
    • Study reports evidence of living with owned systemic/arterial hypertension by one of definition following;
    • Quantitative: Blood pressure number higher over the normal range by each protocol in mmHg unit in any arm of study.
    • Qualitative: Clarify the underwent both retrospective, observation or intervention of blood pressure and clearly clarify number of hypertension participants in article.
    • Study design: any type of studies and have a doi number.
    • In case report type study, the article recruit in only high blood pressure is a burden that reports both direct intervention for blood pressure or indirect intervention such as treatment of vascular damage from high blood pressure.
    • In a group of literature review type study, the number of hypertension participants with references from both in supplementary document or traced back via each doi number have to clearly declare in that free full-text and currently non-retracted article without personal requirement as raw material to processing the individual participant data meta-analysis
    • Study recruit only last version of study series that have to confirm published the hypertension participant with mortality outcomes.
    • English-language studies.
  • Exclusion:
    • Non human/human-specimen studies.
    • Evidence confirms local site or specific system hypertension only such as studies of pulmonary hypertension, portal hypertension, ocular hypertension without clearly defining the number of systemic arterial hypertension in articles.
    • No report of conclusion of participant such as no mortality report, no failed/successful outcome from last follow up from hypertension associated life-threatening event.
    • Deaths due to suicide, trauma, or illegal drugs including intend to take medication overdose in any reason.
    • Book, Testimonial, Interview, Conference, Protocol articles.
    • Sub-group analysis.
    • Duplicate one of the doi/nct/prospero numbers.
    • No doi. Number

Age in the registry: 1 Minute to 130 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Owned study
Coordinator of this site? Confirm its status
BangkokThailandUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.